C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective
E Maddaloni, GB Bolli, BM Frier… - Diabetes, Obesity …, 2022 - Wiley Online Library
Impaired beta‐cell function is a recognized cornerstone of diabetes pathophysiology.
Estimates of insulin secretory capacity are useful to inform clinical practice, helping to …
Estimates of insulin secretory capacity are useful to inform clinical practice, helping to …
Efficacy and safety of once-weekly semaglutide 2· 0 mg versus 1· 0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Background Semaglutide is an effective treatment for type 2 diabetes; however, 20–30% of
patients given semaglutide 1· 0 mg do not reach glycaemic treatment goals. We aimed to …
patients given semaglutide 1· 0 mg do not reach glycaemic treatment goals. We aimed to …
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD‐11
Aim To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in
patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD‐11 trial …
patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD‐11 trial …
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
VR Aroda, R Bauer, E Christiansen… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aims To evaluate the efficacy and safety of oral semaglutide versus comparators by patient
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …
Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes
AM Patti, RV Giglio, A Allotta, A Bruno, T Di Bella… - Biomedicines, 2023 - mdpi.com
Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist.
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
D Yabe, S Deenadayalan, H Horio… - Journal of Diabetes …, 2022 - Wiley Online Library
Abstract Aims/Introduction To assess the impact of baseline characteristics on the efficacy
and safety of oral semaglutide in Japanese patients with type 2 diabetes. Materials and …
and safety of oral semaglutide in Japanese patients with type 2 diabetes. Materials and …
[HTML][HTML] Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
P Marzullo, T Daffara, C Mele, M Zavattaro… - Journal of …, 2022 - Springer
Purpose Registered trials and real-world evidence (RWE) studies provided evidence on the
efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk …
efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk …
Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global …
Early and intensive management of type 2 diabetes has been shown to delay disease
progression, reduce the risk of cardiorenal complications and prolong time to treatment …
progression, reduce the risk of cardiorenal complications and prolong time to treatment …
[HTML][HTML] Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G)
M Ohsugi, K Eguchi, JT Mortensen, Y Yamamoto… - Diabetes Research and …, 2023 - Elsevier
Aims To understand glucagon-like peptide-1 receptor agonist (GLP-1RA) use in patients
with type 2 diabetes (T2D) in Japan. Methods Characteristics of people receiving GLP-1RAs …
with type 2 diabetes (T2D) in Japan. Methods Characteristics of people receiving GLP-1RAs …
[HTML][HTML] The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide
P Kurtzhals, FF Kreiner, RS Bindra - Diabetes Research and Clinical …, 2023 - Elsevier
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used to address multiple
aspects of type 2 diabetes mellitus (T2DM) management, including glycaemic control …
aspects of type 2 diabetes mellitus (T2DM) management, including glycaemic control …